Todd M. Cooper

4.8k total citations
116 papers, 2.0k citations indexed

About

Todd M. Cooper is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Oncology. According to data from OpenAlex, Todd M. Cooper has authored 116 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Hematology, 55 papers in Public Health, Environmental and Occupational Health and 29 papers in Oncology. Recurrent topics in Todd M. Cooper's work include Acute Myeloid Leukemia Research (84 papers), Acute Lymphoblastic Leukemia research (55 papers) and Hematopoietic Stem Cell Transplantation (19 papers). Todd M. Cooper is often cited by papers focused on Acute Myeloid Leukemia Research (84 papers), Acute Lymphoblastic Leukemia research (55 papers) and Hematopoietic Stem Cell Transplantation (19 papers). Todd M. Cooper collaborates with scholars based in United States, Canada and Netherlands. Todd M. Cooper's co-authors include Todd A. Alonzo, Robert B. Gerbing, Soheil Meshinchi, Alan S. Gamis, Betsy Hirsch, Susana C. Raimondi, Lia Gore, Katherine Tarlock, Michael R. Loken and Janet Franklin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Todd M. Cooper

105 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Todd M. Cooper United States	24	1.2k	724	668	667	319	116	2.0k
Barbara De Moerloose Belgium	25	644 0.5×	510 0.7×	454 0.7×	677 1.0×	241 0.8×	127	1.7k
Cristina Papayannidis Italy	26	1.4k 1.2×	951 1.3×	882 1.3×	1.0k 1.5×	508 1.6×	160	2.7k
Ghayas C. Issa United States	24	1.5k 1.3×	751 1.0×	504 0.8×	652 1.0×	631 2.0×	146	2.1k
Massimiliano Bonifacio Italy	23	979 0.8×	902 1.2×	802 1.2×	345 0.5×	417 1.3×	88	2.2k
Anna Tamburini Italy	20	1.1k 0.9×	415 0.6×	256 0.4×	611 0.9×	494 1.5×	40	1.7k
Alice S. Mims United States	23	802 0.7×	193 0.3×	414 0.6×	705 1.1×	187 0.6×	130	1.5k
Tu Xu United States	12	1.9k 1.6×	481 0.7×	438 0.7×	1.3k 1.9×	496 1.6×	29	2.4k
Felicitas Thol Germany	33	2.7k 2.3×	423 0.6×	464 0.7×	2.1k 3.1×	1.1k 3.4×	125	4.0k
Thomas Köhnke Germany	21	902 0.8×	214 0.3×	754 1.1×	637 1.0×	241 0.8×	46	1.8k
Jan Philipp Bewersdorf United States	26	1.1k 1.0×	229 0.3×	372 0.6×	707 1.1×	425 1.3×	137	1.8k

Countries citing papers authored by Todd M. Cooper

Since Specialization

Citations

This map shows the geographic impact of Todd M. Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd M. Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd M. Cooper more than expected).

Fields of papers citing papers by Todd M. Cooper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd M. Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd M. Cooper. The network helps show where Todd M. Cooper may publish in the future.

Co-authorship network of co-authors of Todd M. Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of Todd M. Cooper. A scholar is included among the top collaborators of Todd M. Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd M. Cooper. Todd M. Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huang, Benjamin J., Lauren K. Meyer, Todd A. Alonzo, et al.. (2025). Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 43(17). 1961–1971.

Salzer, Elisabeth, Janine Stutterheim, Branko Cuglievan, et al.. (2024). APAL2020K/ITCC-101: A Phase I Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy in Children with Relapsed/Refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant Acute Leukemias. Blood. 144(Supplement 1). 4265.3–4265.3. 1 indexed citations

Abla, Oussama, Rhonda E. Ries, Timothy J. Triche, et al.. (2024). Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia. Blood Advances. 8(8). 2005–2017. 1 indexed citations

Wachter, Franziska, et al.. (2024). Navigating Treatment Options and Communication in Relapsed Pediatric AML. American Society of Clinical Oncology Educational Book. 44(3). e438690–e438690. 1 indexed citations

Tarlock, Katherine, Robert B. Gerbing, Rhonda E. Ries, et al.. (2024). Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia. Blood Advances. 8(9). 2094–2103. 4 indexed citations

Redell, Michele S., Todd A. Alonzo, Robert B. Gerbing, et al.. (2023). APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias. Blood. 142(Supplement 1). 1492–1492. 1 indexed citations

Cooper, Todd M., Todd A. Alonzo, Sarah K. Tasian, et al.. (2023). Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms. Pediatric Blood & Cancer. 70(S6). e30584–e30584. 9 indexed citations

Raca, Gordana, Todd M. Cooper, Todd A. Alonzo, et al.. (2023). 44. Frequency and etiology of cytogenetically cryptic oncogenic fusions in pediatric AML. Cancer Genetics. 278-279. 14–14.

Tarlock, Katherine, Xiaowei Liu, Charles G. Minard, et al.. (2023). Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712. Pediatric Blood & Cancer. 70(12). e30672–e30672. 2 indexed citations

10.

Lamble, Adam J., Lisa Eidenschink Brodersen, Todd A. Alonzo, et al.. (2021). CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 40(3). 252–261. 26 indexed citations

11.

Sabnis, Himalee S., Katherine A. Minson, Kristen E. Allen, et al.. (2020). A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes. Leukemia Research. 96. 106421–106421. 2 indexed citations

12.

Getz, Kelly, Lillian Sung, Robert B. Gerbing, et al.. (2019). Occurrence and Resolution of Anthracycline Cardiotoxicity and Impact on Treatment Outcomes Among Children Treated on the AAML1031 Clinical Trial: A Report from the Children's Oncology Group. Blood. 134(Supplement_1). 331–331. 2 indexed citations

13.

McNeil, Michael J., Marguerite T. Parisi, Nobuko Hijiya, et al.. (2018). Clinical and Radiographic Response of Extramedullary Leukemia in Patients Treated With Gemtuzumab Ozogamicin. Journal of Pediatric Hematology/Oncology. 41(3). e174–e176. 8 indexed citations

14.

Dvorak, Christopher C., Prakash Satwani, Elliot Stieglitz, et al.. (2018). Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatric Blood & Cancer. 65(7). e27034–e27034. 23 indexed citations

15.

Place, Andrew E., Yana Pikman, Kristen E. Stevenson, et al.. (2018). Phase I trial of the mTOR inhibitor everolimus in combination with multi‐agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatric Blood & Cancer. 65(7). e27062–e27062. 43 indexed citations

16.

Cooper, Todd M., Rhonda E. Ries, Todd A. Alonzo, et al.. (2017). Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood. 130. 407–407. 10 indexed citations

17.

Cooper, Todd M., Elena Eckroth, Jemily Malvar, et al.. (2016). A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clinical Cancer Research. 22(16). 4014–4022. 56 indexed citations

18.

Liu, Xia, Hong Zheng, Wen-Mei Yu, et al.. (2015). Maintenance of mouse hematopoietic stem cells ex vivo by reprogramming cellular metabolism. Blood. 125(10). 1562–1565. 44 indexed citations

19.

Ho, Phoenix A., Todd A. Alonzo, Robert B. Gerbing, et al.. (2013). High EVI 1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group. British Journal of Haematology. 162(5). 670–677. 32 indexed citations

20.

Hijiya, Nobuko, Blythe Thomson, Michael S. Isakoff, et al.. (2011). Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 118(23). 6043–6049. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact